Nuveen Expands Portfolio With Annexon, Inc. (ANNX) Acquisition

Group 1 - Annexon, Inc. (NASDAQ:ANNX) is recognized as a promising fast money stock, with Nuveen LLC acquiring 23,491 shares, representing 0.14% ownership valued at approximately $666,000 [1] - The company is notable for its unique programs, particularly in treating Guillain-Barré syndrome, marking the first such initiative in the last 50 years, highlighting its commitment to patient care [2] - Annexon is also leading a geographic atrophy program, which is the only vision-sparing program globally, having received prime designation, indicating strong future potential [3] Group 2 - Annexon, Inc. is a California-based clinical-stage biopharmaceutical company focused on solutions for inflammatory-related diseases, established in 2011, aiming to address classical complement-driven neuroinflammation [4]